Education
About Us
Working with TipRanks
Follow Us
Exact Sciences Corp. (EXAS)
NASDAQ:EXAS
EXAS Stock Chart & Stats
$67.50
-$1.49(-2.61%)
At close: 4:00 PM EST
$67.50
-$1.49(-2.61%)
Day’s Range― - ―
52-Week Range$38.81 - $72.81
Previous CloseN/A
Volume846.89K
Average Volume (3M)2.59M
Market Cap
$12.61B
Enterprise Value$11.89B
Total Cash (Recent Filing)$1.00B
Total Debt (Recent Filing)$2.54B
Price to Earnings (P/E)―
Beta0.36
Next Earnings
Feb 24, 2026EPS Estimate
-0.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.10
Shares Outstanding189,471,300
10 Day Avg. Volume3,593,173
30 Day Avg. Volume2,591,789
Financial Highlights & Ratios
PEG Ratio-0.03
Price to Book (P/B)4.31
Price to Sales (P/S)3.75
P/FCF Ratio138.84
Enterprise Value/Market Cap0.94
Enterprise Value/Revenue3.86
Enterprise Value/Gross Profit5.73
Enterprise Value/Ebitda-15.61
Forecast
1Y Price Target
$78.31Price Target Upside16.01% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering18
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Product Launch And Market PotentialExact Sciences launched its Multi-Cancer Early Detection (MCED) test, Cancerguard, which addresses approximately 70% of cancers lacking a screening solution, potentially unlocking a $25 billion market.
Revenue Growth And GuidanceExact Sciences reported better than expected results and raised guidance for the remainder of the year.
Strategic PartnershipsAn agreement with Quest Diagnostics supports the Cancerguard product launch, providing access to 7,000 patient sites across the U.S. and mobile phlebotomy services for at-home collections.
Bears Say
Market PositioningCRC blood is viewed as a second-line option compared to Cologuard Plus, indicating a potential limitation in its primary market positioning.
Reimbursement ChallengesMCED screening tests are not yet formally reimbursed, creating uncertainty in achieving full market penetration.
Exact Sciences News
EXAS FAQ
What was Exact Sciences Corp.’s price range in the past 12 months?
Exact Sciences Corp. lowest stock price was $38.81 and its highest was $72.81 in the past 12 months.
What is Exact Sciences Corp.’s market cap?
Exact Sciences Corp.’s market cap is $12.61B.
When is Exact Sciences Corp.’s upcoming earnings report date?
Exact Sciences Corp.’s upcoming earnings report date is Feb 24, 2026 which is in 103 days.
How were Exact Sciences Corp.’s earnings last quarter?
Exact Sciences Corp. released its earnings results on Nov 03, 2025. The company reported -$0.1 earnings per share for the quarter, missing the consensus estimate of -$0.061 by -$0.039.
Is Exact Sciences Corp. overvalued?
According to Wall Street analysts Exact Sciences Corp.’s price is currently Undervalued.
Does Exact Sciences Corp. pay dividends?
Exact Sciences Corp. does not currently pay dividends.
What is Exact Sciences Corp.’s EPS estimate?
Exact Sciences Corp.’s EPS estimate is -0.03.
How many shares outstanding does Exact Sciences Corp. have?
Exact Sciences Corp. has 189,471,300 shares outstanding.
What happened to Exact Sciences Corp.’s price movement after its last earnings report?
Exact Sciences Corp. reported an EPS of -$0.1 in its last earnings report, missing expectations of -$0.061. Following the earnings report the stock price went up 3.897%.
Which hedge fund is a major shareholder of Exact Sciences Corp.?
Currently, no hedge funds are holding shares in EXAS
Exact Sciences Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$78.31 (16.01% Upside)
$78.31 (16.01% Upside)
Blogger Sentiment
Bullish
EXAS Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 958.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 0.2%
Last 30 Days ▲ 8.3%
Last 30 Days ▲ 8.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
31.50%
12-Months-Change
Fundamentals
Return on Equity
-34.54%
Trailing 12-Months
Asset Growth
-12.57%
Trailing 12-Months
Company Description
Exact Sciences Corp.
Exact Sciences Corporation is a molecular diagnostics company based in Madison, Wisconsin, specializing in the early detection and prevention of cancer. The company operates primarily in the healthcare sector, focusing on developing and commercializing innovative testing solutions, particularly in colorectal cancer screening. Its flagship product, Cologuard, is a non-invasive stool-based DNA test that detects signs of colorectal cancer and precancerous polyps. Exact Sciences also offers additional tests aimed at various cancers, contributing to its mission of improving patient outcomes through early diagnosis.
EXAS Company Deck
EXAS Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
Exact Sciences reported strong financial and operational performance with significant revenue growth driven by Cologuard and new product launches. However, there were challenges in maintaining gross margins and completing payer contracts for Cologuard Plus.View all EXAS earnings summariesEXAS Revenue Breakdown
74.59% Screening
25.17% Precision Oncology
0.24% COVID-19 Testing
EXAS Stock 12 Month Forecast
Average Price Target
$78.31
▲(16.01% Upside)
Technical Analysis
Ownership Overview
1.05% Insiders
44.38% Mutual Funds
0.54% Other Institutional Investors
39.60% Public Companies and Individual Investors